Compare Wix.Com Ltd (WIX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wix.Com Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? Wix.Com Ltd trades at $76.07 (market cap $3.11B), while State Street SPDR S&P Biotech ETF trades at $153.99 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 3.3× Wix.Com Ltd's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Wix.Com Ltd for 62 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| WIX | XBI | |
|---|---|---|
Market Cap | $3.11B | $10.11B |
Volume | 809,286 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $145.54 | $169.55 |
52-Week Low | $40.43 | $104.99 |
Typical Hold Time | 62 Days | 38 Days |
Enterprise Value | $4.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
WIX trades at $75.06, up 2.86% today, near the consensus price target of $77.00. The stock shows mixed technical signals with a neutral overall rating but bullish moving averages. Revenue growth is strong, reaching $1.99 billion in 2025, though net income turned positive only recently. However, negative shareholder equity and a class action lawsuit filed in September 2026 present significant headwinds. Analyst sentiment remains largely positive with 63% buy ratings, but recent earnings misses add caution.
The outlook is cautiously optimistic given solid revenue expansion and analyst support, but high valuation multiples, litigation overhang, and inconsistent profitability pose risks. Investors should weigh growth potential against financial stability concerns and legal uncertainties before committing capital.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
